US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Larimar Therapeutics Inc (LRMR) 銘柄情報

Larimar Therapeutics Inc (LRMR)

3.59

0.12

(3.46%)

終了 6月16日 5:00AM

3.6197

0.0297

(0.83%)

取引時間後: 8:50AM

Larimar Therapeutics Inc (LRMR) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

3.6197

( 4.31% )

買値

3.55

売値

3.62

出来高

1,670,492

3.48 日の範囲 3.64

2.22 52 週間の範囲 6.42

時価総額

前日終値

3.47

始値

3.52

時刻

最終取引時間

財務取引量

US$ 5,942,240

VWAP

3.5572

平均取引量 (3 か月)

US$ 1,738,926

発行済株式数

104,382,937

配当利回り

PER

-1.66

1 株当たり利益 (EPS)

-2.09

歳入

-

純利益

-166.01M

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia... Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.larimartx.com

本社

Bala Cynwyd, United States

設立

-

Larimar Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker LRMR. The last closing price for Larimar Therapeutics was US$3.47. Over the last year, Larimar Therapeutics shares have traded in a share price range of US$ 2.22 to US$ 6.42.

Larimar Therapeutics currently has 104,382,937 shares in issue. The market capitalisation of Larimar Therapeutics is US$377.83 million. Larimar Therapeutics has a price to earnings ratio (PE ratio) of -1.66.

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.4097	12.7632398754	3.21	3.73	3.035	2542791	3.46170974	CS
4	0.0397	1.10893854749	3.58	3.73	3.035	1861534	3.4144805	CS
12	-0.9403	-20.6206140351	4.56	5.29	3.035	1703084	4.06576595	CS
26	-0.4803	-11.7146341463	4.1	6.42	2.715	2878836	4.49658373	CS
52	0.7197	24.8172413793	2.9	6.42	2.22	2437290	4.22763676	CS
156	-0.0903	-2.43396226415	3.71	13.68	1.61	1196851	4.63501627	CS
260	-4.6603	-56.2838164251	8.28	15.2581	1.53	779933	4.6633397	CS

LRMR - Frequently Asked Questions (FAQ)

What is the current Larimar Therapeutics Inc share price?

The current share price of Larimar Therapeutics Inc is US$ 3.6197

How many Larimar Therapeutics Inc shares are in issue?

Larimar Therapeutics Inc has 104,382,937 shares in issue

What is the market cap of Larimar Therapeutics Inc?

The market capitalisation of Larimar Therapeutics Inc is USD 377.83M

What is the 1 year trading range for Larimar Therapeutics Inc share price?

Larimar Therapeutics Inc has traded in the range of US$ 2.22 to US$ 6.42 during the past year

What is the PE ratio of Larimar Therapeutics Inc?

The price to earnings ratio of Larimar Therapeutics Inc is -1.66

What is the registered address of Larimar Therapeutics Inc?

The registered address for Larimar Therapeutics Inc is Three Bala Plaza East, Bala Cynwyd, Pennsylvania, 19004

What is the Larimar Therapeutics Inc website address?

The website address for Larimar Therapeutics Inc is www.larimartx.com

Which industry sector does Larimar Therapeutics Inc operate in?

Larimar Therapeutics Inc operates in the Biotechnology & Life Sciences sector

RiskAndReason

RiskAndReason 4月前

LRMR quietly building and the market hasn’t really priced in the upside yet imo. These are the type that move hard once liquidity shows up, i’m watching for momentum shift.

glenn1919

glenn1919 4月前

lrmr............................................https://stockcharts.com/sc3/ui/?s=LRMR&p=w&b=5&g=0&id=p86431144783

tw0122

LRMR above $9 momentarily

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

LRMR new 52 week high

Monksdream

Monksdream 2年前

LRMR new 52=week high

AJ Freely

AJ Freely 3年前

$LRMR - Announced that the FDA has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601
👆Up 8% Pre-Market/ Current Price $3,40

magacrew2020

magacrew2020 3年前

could probably get through approval on just 25 mg if they are going to approve reta

subslover

subslover 4年前

The company said it received feedback from the FDA on information needed to resolve CTI-1601's current clinical hold, as well as a proposed change for a second phase. CTI-1601 is a treatment for Friedreich's ataxia.

Larimer plans to submit a complete response to CTI-1601's clinical hold in the third quarter.

Larimar is also proposing a phase two, four-week dose exploration study in Friedreich's ataxia patients. Friedreich's ataxia is a rare disease that causes progressive nervous system damage and movement problems, usually beginning during childhood.

JJJ54

I voted NO on the 2022 Annual Meeting Vote. I recommend you do the same.

DarkPool

DarkPool 4年前

oxnous

Waking up . But volume should be higher.

DewDiligence

DewDiligence 6年前

LRMR 2Q20 results—6/30/20 cash=$113.7M:

https://www.globenewswire.com/news-release/2020/08/11/2076240/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2020-Operating-and-Financial-Results.html

No CC.

casenumber

casenumber 6年前

Large chunks are being gobbled
Whales are lurking around?

subslover

subslover 6年前

The company they are merging with looks pretty darn impressive
https://chondrialtherapeutics.com/

casenumber

casenumber 6年前

ClayTrader

ClayTrader 6年前

* * $ZFGN Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

ClayTrader

ClayTrader 6年前

* * $ZFGN Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

whytestocks

whytestocks 6年前

News: $ZFGN Penny Stocks To Buy Or Sell Before The End Of 2019?

These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...

Got this from ZFGN - Penny Stocks To Buy Or Sell Before The End Of 2019?

Master_Chief_117

Master_Chief_117 6年前

Like I said at .67 cents

ClayTrader

ClayTrader 6年前

* * $ZFGN Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

casenumber

casenumber 6年前

Wow...guess they will satisfy the 1dollar minimum nasd requirement with out rs.....
This will be huge when ticker change and merger consummated next month!

Scrap the notice of delisting boys.....

82M cash and 30M OS....sounds fun!

ClayTrader

ClayTrader 6年前

* * $ZFGN Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

casenumber

casenumber 6年前

Over a buck soon when ticker change completed....

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

exactly is great

Master_Chief_117

Master_Chief_117 6年前

Probably 3-9 months away still - appears to be a massive over correction and tax loss selling on the merger news. Just a short target at the moment. They will run this in Q1 pre-split to get a much more favorable ratio IMO. Let's see what happens. Lots of cash on hand here at very low burn rate per Q.

The transaction is expected to close in the first half of 2020, subject to approvals by stockholders of each company and other customary closing conditions.

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

R/Split coming per 8k today

Master_Chief_117

Master_Chief_117 6年前

December discounts. With 85 million in cash, a merger, and priced at 67 cents there's no way this doesn't run soon. 35 million O/S.

casenumber

casenumber 6年前

Ticker change coming...Shorts will get burn if they will not cover or do damage control.
ZFGN has 82M dollars in cash!

The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.

casenumber

casenumber 6年前

Shorts covering.. they have to before it gets out of control once the merger is official...

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

10 day MA live chart huge oversold,safe here now,will recover nice

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

bought 3k at 6391

Master_Chief_117

Master_Chief_117 6年前

Just saw a bunch come through on tape that were vastly different but didn't indicate "out of sequence"...they were either out of sequence or it was a messed up market order. Just odd. This one is clearly under short attack. Volume could squeeze it near term.

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

ZFGN~~Balance Sheet
Total Cash (mrq) 82.01M
Total Cash Per Share (mrq) 2.19
Total Debt (mrq) 24.35M
Total Debt/Equity (mrq) 40.67
Current Ratio (mrq) 5.11
Book Value Per Share (mrq) 1.60
https://finance.yahoo.com/quote/ZFGN/key-statistics?p=ZFGN

alchemytrader

alchemytrader 6年前

not really. that would mean its been up and down, up and down. this is nothing but down..

Master_Chief_117

Master_Chief_117 6年前

...this price action is ALL over the place. Crazy.

alchemytrader

alchemytrader 6年前

man i hope so. just want out even now

BoilerRoom

BoilerRoom 6年前

$ZFGN in at .70

BoilerRoom

BoilerRoom 6年前

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

will recover but sucks,waste of time

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m.,

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

Conference Call Information
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m., Eastern Time, to discuss the merger as well as other forward-looking information. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 5688136. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 11:30 a.m. ET on December 18, 2019 through December 25, 2019 by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States. To access the replay please provide Conference ID number 5688136.

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

Widowsson32

Widowsson32 6年前

This is done no benefit to this company but ONTX will make you very rich

alchemytrader

alchemytrader 6年前

institutions selling off?

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

the news is great,why?

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

fffffffffffffffffff MMS

alchemytrader

alchemytrader 6年前

i guess were screwed

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 6年前

Larimar Therapeutics

Amundi FTSE MIB UCITS ET...

Galera Therapeutics (QB)

Agf Global Income Portfo...

Ag Europe Realty Fund Ii

Fota Sa W Upadlosci Ukla...

Tion Renewables

Franklin Templeton ICAV

Avalo Therapeutics

Eqty Lkd Nts 26/12/28

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。